{
    "clinical_study": {
        "@rank": "126120", 
        "arm_group": [
            {
                "arm_group_label": "sugar pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "esomeprazole 40mg twice daily or matching placebo."
            }, 
            {
                "arm_group_label": "esomeprazole", 
                "arm_group_type": "Active Comparator", 
                "description": "esomeprazole 40mg twice daily will be compared to matching placebo twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "Gastroesophageal reflux disease is a common problem in cystic fibrosis(CF). It may lead to\n      worsening lung function and more respiratory infections for a person with CF. This study\n      will look at treating GERD with a medication, esopmeprazole. The medication stops stomach\n      acid from being made. The study will see if there are fewer respiratory infections and\n      improved lung function in patients with CF when taking esomeprazole."
        }, 
        "brief_title": "Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, placebo controlled intervention study in patients with CF who have a\n      history of frequent exacerbations. Treatment duration is 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Cystic fibrosis\n\n          2. Age > 18 years\n\n          3. Stable maintenance medical regimen during the previous 6 weeks.\n\n          4. Negative pregnancy test (women of childbearing potential) at both screening and\n             baseline visits.\n\n          5. Women of childbearing potential must be using medically acceptable contraception.\n\n          6. At least two respiratory exacerbations per year requiring oral and/or intravenous\n             antibiotics for each of  the two years prior to study entry, but no more than 4\n             exacerbations requiring intravenous antibiotics during either of those years.\n\n        Exclusion Criteria:\n\n          1. Previous anti-reflux or peptic ulcer surgery,\n\n          2. Use of PPI within the past two weeks\n\n          3. Pulmonary exacerbation requiring antibiotics within the previous 2 weeks\n\n          4. Parenteral hyperalimentation\n\n          5. Cigarette smoking\n\n          6. Treatment with azoles, iron, anti-coagulants, digitalis\n\n          7. Use of any investigative drugs within the previous month.\n\n          8. Use of over the counter acid suppressor agents (not including acid neutralizers)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01983774", 
            "org_study_id": "AAAC5640"
        }, 
        "intervention": {
            "arm_group_label": "esomeprazole", 
            "intervention_name": "esomeprazole", 
            "intervention_type": "Drug", 
            "other_name": "nexium"
        }, 
        "intervention_browse": {
            "mesh_term": "Proton Pump Inhibitors"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "CF", 
        "lastchanged_date": "November 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10003"
                }, 
                "name": "Beth Israel Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Proton Pump Inhibitors on CF Exacerbations", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Time to need for oral or intravenous antibiotics for treatment of a pulmonary exacerbation is the primary outcome measure.", 
            "measure": "Time to first pulmonary exacerbation", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01983774"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Columbia University", 
            "investigator_full_name": "Emily DiMango, MD", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Forced Expiratory Volume in one second (FEV1)", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Forced Vital Capacity (FVC)", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Number of exacerbations", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Columbia University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Columbia University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}